{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T20:06:33Z","timestamp":1788552393721,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,19]]},"DOI":"10.7759\/cureus.103927","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T22:07:46Z","timestamp":1771538866000},"source":"Crossref","is-referenced-by-count":2,"title":["Effects of GLP-1 Receptor Agonists vs Metformin in Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Khuloud","family":"Almubaddil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manal","family":"Alotaibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Bin Mutreb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fouz","family":"Alanazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Msaad","family":"Altulihee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/des232","article-title":"Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria","volume":"27","author":"Yildiz BO","year":"2012","unstructured":"Yildiz BO, Bozdag G, Yapici Z, Esinler I, Yarali H. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod. 2012, 27:3067-73. 10.1093\/humrep\/des232","journal-title":"Hum Reprod"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/s0889-8545(05)70188-1","article-title":"Diabetes prevalence and risk factors in polycystic ovary syndrome","volume":"28","author":"Legro RS","year":"2001","unstructured":"Legro RS. Diabetes prevalence and risk factors in polycystic ovary syndrome. Obstet Gynecol Clin N Am. 2001, 28:99-109. 10.1016\/s0889-8545(05)70188-1","journal-title":"Obstet Gynecol Clin N Am"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2004.11.070","article-title":"Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment","volume":"83","author":"DeUgarte CM","year":"2005","unstructured":"DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril. 2005, 83:1454-60. 10.1016\/j.fertnstert.2004.11.070","journal-title":"Fertil Steril"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa285","article-title":"Obesity, polycystic ovary syndrome, and infertility: a new avenue for GLP-1 receptor agonists","volume":"105","author":"Cena H","year":"2020","unstructured":"Cena H, Chiovato L, Nappi RE. Obesity, polycystic ovary syndrome, and infertility: a new avenue for GLP-1 receptor agonists. J Clin Endocrinol Metab. 2020, 105:e2695-709. 10.1210\/clinem\/dgaa285","journal-title":"J Clin Endocrinol Metab"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2017.1292125","article-title":"GLP-1 receptor agonists in the treatment of polycystic ovary syndrome","volume":"10","author":"Lamos EM","year":"2017","unstructured":"Lamos EM, Malek R, Davis SN. GLP-1 receptor agonists in the treatment of polycystic ovary syndrome. Expert Rev Clin Pharmacol. 2017, 10:401-8. 10.1080\/17512433.2017.1292125","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-021-01671-z","article-title":"How to properly use the PRISMA statement","volume":"10","author":"Sarkis-Onofre R","year":"2021","unstructured":"Sarkis-Onofre R, Catal\u00e1-L\u00f3pez F, Aromataris E, Lockwood C. How to properly use the PRISMA statement. Syst Rev. 2021, 10:117. 10.1186\/s13643-021-01671-z","journal-title":"Syst Rev"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins JP","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, et al.. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011, 343:d5928. 10.1136\/bmj.d5928","journal-title":"BMJ"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1057\/s41270-022-00184-5","article-title":"Comprehensive Meta-Analysis (CMA) 3.0: a software review","volume":"10","author":"Br\u00fcggemann P","year":"2022","unstructured":"Br\u00fcggemann P, Rajguru K. Comprehensive Meta-Analysis (CMA) 3.0: a software review. J Market Anal. 2022, 10:425-9. 10.1057\/s41270-022-00184-5","journal-title":"J Market Anal"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-015-0161-3","article-title":"Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study","volume":"8","author":"Jensterle M","year":"2015","unstructured":"Jensterle M, Salamun V, Kocjan T, Vrtacnik Bokal E, Janez A. Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study. J Ovarian Res. 2015, 8:32. 10.1186\/s13048-015-0161-3","journal-title":"J Ovarian Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/BF03401383","article-title":"A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome","volume":"14","author":"Jensterle M","year":"2015","unstructured":"Jensterle M, Kravos NA, Pfeifer M, Kocjan T, Janez A. A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome. Hormones (Athens). 2015, 14:81-90. 10.1007\/BF03401383","journal-title":"Hormones (Athens)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa692","article-title":"Exenatide, metformin, or both for prediabetes in PCOS: a randomized, open-label, parallel-group controlled study","volume":"106","author":"Tao T","year":"2021","unstructured":"Tao T, Zhang Y, Zhu YC, et al.. Exenatide, metformin, or both for prediabetes in PCOS: a randomized, open-label, parallel-group controlled study. J Clin Endocrinol Metab. 2021, 106:e1420-32. 10.1210\/clinem\/dgaa692","journal-title":"J Clin Endocrinol Metab"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ18-0153","article-title":"Circulating zinc-\u03b12-glycoprotein is reduced in women with polycystic ovary syndrome, but can be increased by exenatide or metformin treatment","volume":"66","author":"Zheng S","year":"2019","unstructured":"Zheng S, Liu E, Zhang Y, et al.. Circulating zinc-\u03b12-glycoprotein is reduced in women with polycystic ovary syndrome, but can be increased by exenatide or metformin treatment. Endocr J. 2019, 66:555-62. 10.1507\/endocrj.EJ18-0153","journal-title":"Endocr J"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1177\/1933719116635278","article-title":"Effects of exenatide on metabolic changes, sexual hormones, inflammatory cytokines, adipokines, and weight change in a DHEA-treated rat model","volume":"23","author":"Sun L","year":"2016","unstructured":"Sun L, Ji C, Jin L, et al.. Effects of exenatide on metabolic changes, sexual hormones, inflammatory cytokines, adipokines, and weight change in a DHEA-treated rat model. Reprod Sci. 2016, 23:1242-9. 10.1177\/1933719116635278","journal-title":"Reprod Sci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-015-3976-7","article-title":"A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries","volume":"293","author":"Niafar M","year":"2016","unstructured":"Niafar M, Pourafkari L, Porhomayon J, Nader N. A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries. Arch Gynecol Obstet. 2016, 293:509-15. 10.1007\/s00404-015-3976-7","journal-title":"Arch Gynecol Obstet"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1530\/EC-17-0239","article-title":"Adrenal hyperandrogenism does not deteriorate insulin resistance and lipid profile in women with PCOS","volume":"6","author":"Paschou SA","year":"2017","unstructured":"Paschou SA, Palioura E, Ioannidis D, et al.. Adrenal hyperandrogenism does not deteriorate insulin resistance and lipid profile in women with PCOS. Endocr Connect. 2017, 6:601-6. 10.1530\/EC-17-0239","journal-title":"Endocr Connect"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2014.06.003","article-title":"DHEA, DHEAS and PCOS","volume":"145","author":"Goodarzi MO","year":"2015","unstructured":"Goodarzi MO, Carmina E, Azziz R. DHEA, DHEAS and PCOS. J Steroid Biochem Mol Biol. 2015, 145:213-25. 10.1016\/j.jsbmb.2014.06.003","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dex308","article-title":"Insulin resistance in a large cohort of women with polycystic ovary syndrome: a comparison between euglycaemic-hyperinsulinaemic clamp and surrogate indexes","volume":"32","author":"Tosi F","year":"2017","unstructured":"Tosi F, Bonora E, Moghetti P. Insulin resistance in a large cohort of women with polycystic ovary syndrome: a comparison between euglycaemic-hyperinsulinaemic clamp and surrogate indexes. Hum Reprod. 2017, 32:2515-21. 10.1093\/humrep\/dex308","journal-title":"Hum Reprod"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s12905-025-03594-6","article-title":"Comparative efficacy of pharmacological interventions on metabolic and hormonal outcomes in polycystic ovary syndrome: a network meta-analysis of randomized controlled trials","volume":"25","author":"Bo Y","year":"2025","unstructured":"Bo Y, Zhao J, Liu C, Yu T. Comparative efficacy of pharmacological interventions on metabolic and hormonal outcomes in polycystic ovary syndrome: a network meta-analysis of randomized controlled trials. BMC Womens Health. 2025, 25:64. 10.1186\/s12905-025-03594-6","journal-title":"BMC Womens Health"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2024.108834","article-title":"The efficacy and safety of GLP-1 agonists in PCOS women living with obesity in promoting weight loss and hormonal regulation: a meta-analysis of randomized controlled trials","volume":"38","author":"de Hollanda BA","year":"2024","unstructured":"de Hollanda BA, Priz\u00e3o VM, de Souza MD, Mendes BX, Defante ML, Martins OC, Rodrigues AM. The efficacy and safety of GLP-1 agonists in PCOS women living with obesity in promoting weight loss and hormonal regulation: a meta-analysis of randomized controlled trials. J Diabetes Complications. 2024, 38:108834. 10.1016\/j.jdiacomp.2024.108834","journal-title":"J Diabetes Complications"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s43032-023-01222-y","article-title":"The effectiveness and safety of exenatide versus metformin in patients with polycystic ovary syndrome: a meta-analysis of randomized controlled trials","volume":"30","author":"Ye ZR","year":"2023","unstructured":"Ye ZR, Yan CQ, Liao N, Wen SH. The effectiveness and safety of exenatide versus metformin in patients with polycystic ovary syndrome: a meta-analysis of randomized controlled trials. Reprod Sci. 2023, 30:2349-61. 10.1007\/s43032-023-01222-y","journal-title":"Reprod Sci"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01779-z","article-title":"The effect of oral antidiabetic drugs on improving the endocrine and metabolic states in women with polycystic ovary syndrome: a systematic review and network meta-analysis","volume":"82","author":"Yang S","year":"2022","unstructured":"Yang S, Zhao L, He W, Mi Y. The effect of oral antidiabetic drugs on improving the endocrine and metabolic states in women with polycystic ovary syndrome: a systematic review and network meta-analysis. Drugs. 2022, 82:1469-80. 10.1007\/s40265-022-01779-z","journal-title":"Drugs"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/460758-effects-of-glp-1-receptor-agonists-vs-metformin-in-polycystic-ovary-syndrome-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T22:07:47Z","timestamp":1771538867000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/460758-effects-of-glp-1-receptor-agonists-vs-metformin-in-polycystic-ovary-syndrome-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.103927","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,19]]}}}